Table 4.
Changes in TBRmax Open-Label Extension
| Mean (P Value*) | |
|---|---|
| Global change baseline compared with end of open-label extension (n=38) | |
| Difference | −0.015 (0.672) |
| % change (95% CI) | 0.84% (−4.38% to 6.07%); (0.746) |
| Global change start of ustekinumab compared with end of open-label extension (n=38) | |
| Difference | −0.025 (0.433) |
| % change (95% CI) | −0.38% (−5.02% to 4.25%); (0.868) |
CI indicates confidence interval; and TBR, target-to-background ratio.
*
One sample test (P value).
Results with NIH-read images.